Measurement characteristics of a new rapid anti‐CCP2 test compared to the anti‐CCP2 ELISA

Snijders, G.F.; Broeder, Alfons A den; Bevers, K.; Jeurissen, M. E. C.; Eerd, J. E. van; Hoogen, F.H.J. van den

doi:10.1080/03009740701867331

Cited by 11 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Point-of-care tests with the advantage of immediate results are rarely needed, offering qualitative (positive/negative) results for selected biomarkers, with varying concordance 46 compared with laboratory-based testing: (anti-CCP2: sensitivity and specificity of 95% 47 to 100% 48 ; anti-MCV 49 : sensitivity 69.3%, specificity 99.7%; RF IgG 49 : sensitivity 69.3%, specificity 99.7%).…”

Section: Discussionmentioning

confidence: 99%

Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo evaluate the feasibility, accuracy, usability and acceptability of two upper arm self-sampling devices for measurement of autoantibodies and C reactive protein (CRP) levels in patients with immune-mediated rheumatic diseases (IMRDs).Methods70 consecutive patients with IMRD with previously documented autoantibodies were assigned to supervised and unsupervised self-collection of capillary blood with the Tasso+ or TAP II device. Interchangeability of 17 biomarkers with standard venesection was assessed by: concordance, correlation, paired sample hypothesis testing and Bland-Altman plots. Patients completed an evaluation questionnaire, including the System Usability Scale (SUS) and Net Promoter Score (NPS).ResultsWhile 80.0% and 77.0% were able to safely and successfully collect capillary blood using the Tasso+ and TAP II within the first attempt, 69 of 70 (98.6%) patients were successful in collecting capillary blood within two attempts. Concordance between venous and capillary samples was high; 94.7% and 99.5% for positive and negative samples, respectively. For connective tissue disease screen, anti-Ro52 and anti-proteinase 3 autoantibody levels, no significant differences were observed. Self-sampling was less painful than standard venesection for the majority of patients (Tasso+: 71%; TAP II: 63%). Both devices were well accepted (NPS; both: +28%), usability was perceived as excellent (SUS; Tasso+: 88.6 of 100; TAP II: 86.0 of 100) and 48.6 %/62.9% of patients would prefer to use the Tasso+/TAP II, respectively, instead of a traditional venous blood collection.ConclusionsRemote self-collection of capillary blood using upper arm-based devices for autoantibody and CRP analysis in patients with autoimmune rheumatic diseases is feasible, accurate and well accepted among patients.Trial registration numberWHO International Clinical Trials Registry (DRKS00024925).

show abstract

Section: Discussionmentioning

confidence: 99%

Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Knowledge on the citrullinome (total repertoire of citrullinated proteins in a defined tissue), the application of array‐based screening technologies, 131 and use of automated assays 132 will undoubtedly further increase the diagnostic potential of these autoantibodies. In this respect it is also interesting to note that a more rapid anti‐CCP2 assay, the CCPoint assay (Euro‐Diagnostica, Arnhem, The Netherlands), allowing for an immediate diagnosis (10 minutes) is now available for use in an outpatient clinic 133 …”

Section: Future Perspectivesmentioning

confidence: 99%

Anti‐CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis

Venrooij

Beers

Pruijn

2008

Annals of the New York Academy of Sciences

166

104

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic inflammation of synovial joints. In most cases this will lead to the formation of pannus tissue, ultimately leading to joint destruction. Early diagnosis, coupled with aggressive use of disease-modifying antirheumatic drugs, has been shown to have a favorable effect on the course of the disease. Therefore, early and accurate diagnosis has become increasingly important. Several sets of criteria have been published to achieve such an early diagnosis, and all of them include measurement of antibodies directed to citrullinated peptides or proteins. This review summarizes our present knowledge about the most well-known and established test to measure these antibodies, the anti-CCP test, which measures antibodies directed to cyclic citrullinated peptides. We describe the current views on how these antibodies are generated and how genetic and environmental parameters are important in this process. The anti-CCP test is more specific than the commonly used RF test (95% versus less than 90%) and has a comparable sensitivity (more than 70%). These antibodies are detectable very early in the disease and are reported to predict the development of erosive RA. Increasing evidence supports a role for these antibodies in the pathology of the disease. In conclusion, testing for anti-CCP autoantibodies is widely accepted as an indispensable tool for diagnosis and early treatment in the management of rheumatoid arthritis patients.

show abstract

“…The Rheuma-Chec test (Orgentec, Mainz, Germany) combines two biomarkers for the diagnosis of RArheumatoid factor and antibodies to MCV. Antibodies to CCP are detected with the CCPoint assay (Euro-Diagnostica, Malmö, Sweden) (25). The tests require only a single drop of whole blood and any general physician can perform them within minutes.…”

Section: Point-of-care Tests (Poct)mentioning

confidence: 99%

The Serological Diagnosis of Rheumatoid Arthritis

Egerer

Feist²,

Burmester³

2009

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

show abstract

Measurement characteristics of a new rapid anti‐CCP2 test compared to the anti‐CCP2 ELISA

Abstract: The CCPoint test is a fast, valid and reliable anti-CCP2 test in both capillary blood and serum but not directly in venous blood.

Cited by 11 publications

References 7 publications

Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases

Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases

Anti‐CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis

The Serological Diagnosis of Rheumatoid Arthritis

Contact Info

Product

Resources

About